Table 3. Association between treatment-induced increases of CK18-Asp396 and CK18 and baseline levels of PSA, CK18 or CK18-Asp396.
| Baseline PSA | CK18-Asp396 increase (U l−1) docetaxel | CK18 increase (U l−1) docetaxel | CK18-Asp396 increase (U l−1) vinorelbine | CK18 increase (U l−1) vinorelbine | CK18 increase (U l−1) EMP |
|---|---|---|---|---|---|
| First quartile | 13 (−4–50) | 53 (−1–183) | 7 (−4–36) | 0 (−54–68) | 23 (−21–87) |
| Second quartile | 24 (2–66) | 62 (4–148) | 9 (−11–25) | 7 (−46–85) | −1 (−83–53) |
| Third quartile | 22 (−4–55) | 50 (−16–187) | 10 (−11–43) | 13 (−50–90) | 22 (−54–79) |
| Fourth quartile | 82 (−23–126) P=0.02a | 47 (−48–237) | 7 (−3–35) | 22 (−60–321) P=0.10 | −7 (−144–124) |
| Baseline CK18 | |||||
| First quartile | 22 (0–53) | 22 (−23–152) | 7 (−10–26) | 0 (−48–63) | 30 (−14–86) |
| Second quartile | 18 (0–53) | 61 (−27–165) | 6 (−8–20) | 20 (−14–90) | 11 (−33–73) |
| Third quartile | 13 (−13–47) | 21 (−19–121) | 14 (−2–45) | 7 (−46–86) | 0 (−84–62) |
| Fourth quartile | 92 (15–169) P=0.0002 | 136 (10–423) P=0.006 | 7 (−6–49) | 24 (−96–130) P=0.31 | −59 (−251–124) |
| Baseline CK18-Asp396 | |||||
| First quartile | 13 (−1–43) | 16 (−30–108) | 7 (−6–19) | 4 (−52–64) | 29 (−28–83) |
| Second quartile | 11 (−4–46) | 56 (−34–123) | 7 (−8–31) | 3 (−37–95) | 2 (−54–67) |
| Third quartile | 42 (0–91) | 97 (1– 216) | 6 (−7–31) | 12 (−57–104) | −2 (−110–75) |
| Fourth quartile | 54 (1–151) P=0.004 | 87 (−3–232) P=0.06 | 16 (−7–81) P=0.08 | 38 (−69–136) P=0.15 | 14 (−116–117) |
a
Wilcoxon Two-Sample test; comparing the median level of the lowest and highest quartile.
CK18=Cytokeratin 18; PSA=prostate-specific antigen.